Director/PDMR Shareholding

RNS Number : 0420M

Nuformix PLC

16 September 2021

 

16 September 2021

Nuformix plc

("Nuformix" or the "the Company")

Director/PDMR Shareholding

Nuformix plc  (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that today the Company received notice that Dr Alastair Riddell, Chairman of the Company, purchased 350,000 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 0.0135 pence per share on 16 September 2021.

- Ends -

  Enquiries:

Nuformix plc	[phone]
Dr Anne Brindley, CEO
Allenby Capital Limited	[phone]
Nick Athanas / George Payne (Corporate Finance)
Stefano Aquilino / Matt Butlin (Sales & Corporate Broking)
Walbrook PR Anna Dunphy / Paul McManus	[phone] [e-mail]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr Alastair Riddell
2	Reason for the notification
a)	Position/status	PDMR - Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Nuformix plc
b)	LEI	2138003XG3H3I2J3BJ24
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of nominal value 0.1 pence each GB00BYW79Y38
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 0.0135p 350,000
d)	Aggregated information - Aggregated volume - Price - Total	350,000 0.0135p £4,725.00
e)	Date of the transaction	16 September 2021
f)	Place of the transaction	London Stock Exchange, Main Market

 

END

 

 

DSHGPUACBUPGGGQ